| Follow Us: Facebook Twitter

News

NextGen Metabolomics develops blood reading tech, to add 8 jobs

If we are what we eat, then the bibliography of our life is in our blood. NextGen Metabolomics is working on new technology that will tell us where the best information is today and what's not worth reading.

"There has been a real need that isn't being met in the market today," says Felice de Jong, CEO of NextGen Metabolomics. "Metabolomics is the fastest growing sector in life sciences today."

NextGen Metabolomics' technology will read the information in the blood to help diagnose diseases like cholesterol and diabetes. De Jong says the product will distinguish itself because it can cut through all of the information clutter in blood to the valuable 20 percent that relates to disease and illness. "Instead of hours to interpret the data, it only takes minutes," de Jong says.

The Ann Arbor-based firm got its start last June and has received two patents. The two-person team, which made the semi-finals of the Accelerate Michigan Innovation Competition, is currently fundraising so it can finish developing
and licensing the technology and building applications around it. De Jong expects her company to ramp up staffing to 10 employees by next year and 25 within a few years.

Source: Felice de Jong, CEO of NextGen metabolomics
Writer: Jon Zemke

Signup for Email Alerts
Signup for Email Alerts

Related Company

  • NextGen Metabolomics
    Ann Arbor, MI 48104 Website
    NextGen metabolomics is developing technology that reads the information in the blood to help diagnose diseases like cholesterol and diabetes. The technology will cut through all of the information clutter in blood to the valuable 20 percent that ...